Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 31.80 as of 2026-10-06T17:17:09.870Z.
Consensus retrieved: 2026-10-06T13:26:58.036Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:17:09.870Z.
Quote observation: 2026-10-06T17:15:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1d61cb526df749638d8a03bd9b53720723668f0aa6d8453294d9eed2d0ae833
Forward PE Ratio (31.80) = Dated Quote Price ($295.91) / Consensus Forward EPS ($9.31)
FORWARD PE RATIO
31.80
SECTOR MEDIAN · HEALTHCARE
19.75
median of 182 covered companies
CURRENT VS SECTOR MEDIAN
+61.01%
vs the sector median at left
Ligand Pharmaceuticals Incorporated
Market Cap
$5.93B
Forward PE Ratio
31.80
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | $5.93B | 31.80 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.93B | N/A |
| GRAIL Inc. (GRAL)vs › | $6.03B | N/A |
| Kodiak Sciences Inc. (KOD)vs › | $5.78B | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 54.12 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.20B | N/A |
| CG Oncology Inc. (CGON)vs › | $5.62B | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | 136.76 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 29.18 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 19.86 |
Trailing P/E
31.6
reported TTM EPS
Forward P/E
31.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $9.31 implies -0.4% EPS decline vs the reported trailing $9.35.
At the dated quote price of $295.91, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $9.31 | $9.13 – $9.54 | 7 | 31.8x |
| 2027-12-31 | $12.11 | $11.73 – $12.70 | 7 | 24.4x |
| 2028-12-31 | $14.58 | $13.85 – $15.32 | 5 | 20.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
